Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b

Journal of Medical Virology

Volumn 85, Issue 7, 2013, Pages 1180-1190

  Yoshizawa, Kai ^a   Abe, Hiroshi ^a   Aida, Yuta ^a   Ishiguro, Haruya ^a   Ika, Makiko ^b   Shimada, Noritomo ^b   Tsubota, Akihito ^a   Aizawa, Yoshio ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shinmatsudo Central General Hospital   (Japan)

Author keywords

Hepatitis C virus (HCV); Lipid metabolism; Pegylated interferon (Peg IFN); Ribavirin (RBV)

Indexed keywords

ALPHA FETOPROTEIN; APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN; PEGINTERFERON; RIBAVIRIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE;

HEPATITIS C VIRUS (HCV); LIPID METABOLISM; PEGYLATED INTERFERON (PEG-IFN); RIBAVIRIN (RBV);

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; APOLIPOPROTEIN B-100; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; RIBAVIRIN; SERUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878230308     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23597     Document Type: Article

References (39)

1. Aizawa Y, Yohizawa K, Aida Y, Ishiguro H, Abe H, Tsubota A. 2012. Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. Mol Cell Biochem 360:9-14.
2. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410.
3. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. 2010. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429.
4. Alvisi G, Madan V, Bartenschlager R. 2011. Hepatitis C virus and host cell lipids: An intimate connection. RNA Biol 8:258-269.
5. Backus LI, Boothroyd DB, Phillips BR, Mole LA. 2007. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46:37-47.
6. Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. 2010. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C. Hepatol Res 40:1155-1167.
7. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML. 2009. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 50:712-718.
8. Economou M, Milionis H, Filis S, Baltayiannis G, Christou L, Elisaf M, Tsianos E. 2008. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 23:586-591.
9. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Jr., Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
11. Friedewald WT, Levy RI, Fredrickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502.
12. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. 2008. Cellular determinants of hepatitis C virus assembly, maturation, degradation and secretion. J Virol 82:2120-2129.
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
14. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:1335-1374.
15. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr., Ye J. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 104:5848-5853.
16. Kinoshita M, Kojima M, Matsushima T, Teramoto T. 2005. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 351:115-120.
17. Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Miyakawa Y, Kumada H. 2012. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1, 518 patients infected with hepatitis C virus. J Gastroenterol 47:596-605.
18. Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N. 2011. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol 46:401-409.
19. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, McHutchison JG, McCarthy JJ. 2010. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51:1904-1911.
20. Lin C, Kwong AD, Perni RB. 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 6:3-16.
21. Maillard P, Walic M, Meuleman P, Roohvand F, Huby T, Le Goff W, Leroux-Roels G, Pécheur EI, Budkowska A. 2011. Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. PLoS ONE 6:e26637.
22. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. 2012. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol 56:1276-1282.
23. Meredith LW, Wilson GK, Fletcher NF, McKeating JA. 2012. Hepatitis C virus entry: Beyond receptors. Rev Med Virol 22:182-193.
24. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. 2006. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analysed in iodixanol density gradients. J Virol 80:2418-2428.
25. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, Hiraga N, Kawakami Y, Aimitsu S, Kao JH, Kubo M, Tsunoda T, Kumada H, Nakamura Y, Hayes CN, Chayama K. 2011. IL-28B predicts response to chronic hepatitis C therapy-Fine-mapping and replication study in Asian populations. J Gen Virol 92:1071-1081.
26. Petit JM, Carrat F, Duong M, Halfon P, Duvillard L, Bani-Sadr F, Chavanet P, Cacoub P, Piroth L. 2010. Response to anti-HCV therapy in HIV-HCV-coinfected patients: Does the lipid profile really have an effect? Antivir Ther 15:797-800.
27. Poordad F, Reddy KR, Martin P. 2008. Rapid virologic response: A new milestone in the management of chronic hepatitis C. Clin Infect Dis 46:78-84.
28. Popescu CI, Dubuisson J. 2009. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell 102:63-74.
29. Sabahi A, Marsh KA, Dahari H, Corcoran P, Lamora JM, Yu X, Garry RF, Uprichard SL. 2010. The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology 407:110-119.
30. Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2009. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 54:1317-1324.
31. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-567.
32. Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, Bassendine MF. 2009. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther 29:1282-1290.
33. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104.
34. Syed GH, Amako Y, Siddqui A. 2010. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 21:33-40.
35. Targett-Adams P, Boulant S, Douglas MW, McLauchlan J. 2010. Lipid metabolism and HCV infection. Viruses 2:1195-1217.
36. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109.
37. Welsch C, Jesudian A, Zeuzem S, Jacobson I. 2012. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61:i36-i46.
38. Williams R. 2006. Global challenges in liver disease. Hepatology 44:521-526.
39. Young SG. 1990. Recent progress in understanding apolipoprotein B. Circulation 82:1574-1594.